Gadolinium Deposition in Neurology Clinical Practice.

Conclusion: Clear evidence demonstrates that GBCAs lead to gadolinium deposition in the brain in a dose-dependent manner; however, only linear GBCAs have been associated with gadolinium deposition visualized on MRI. To date, no evidence links gadolinium deposition with any adverse health outcome. Updated medical society guidelines emphasize the importance of an individualized risk-benefit analysis with each administration of GBCAs. PMID: 30983897 [PubMed]
Source: Ochsner Journal - Category: General Medicine Tags: Ochsner J Source Type: research